

**NOW**

IMPROVED WORKFLOW

WITH SINGLE PATIENT SWAB FOR  
COVID-19 AND INFLUENZA A & B

HIGH-PERFORMANCE RESULTS

# ID NOW™

RAPID MOLECULAR  
RESPIRATORY TESTING  
PLATFORM

DIAGNOSES COVID-19, INFLUENZA, RSV AND STREP A IN REAL TIME



FASTER LIFE-SAVING DECISIONS



# ID NOW™

PROVIDES RESULTS  
EXACTLY WHEN  
AND WHERE THEY  
ARE NEEDED.

The lab of the future elevates diagnostics beyond one physical location and recentralizes it around the patient, where acute care is delivered. The rapid molecular ID NOW™ Platform flexibly tests for COVID-19, influenza, RSV and strep A and allows lab directors to maintain control of high-performance diagnostics while empowering physicians to make faster decisions with diagnostic results in real time.






# GET REAL-TIME MOLECULAR DIAGNOSTICS **NOW**

In 13 minutes or less, the speed and PCR-like sensitivity of **ID NOW™** enhances clinical confidence and allows immediate decision-making.

- Know positive results in six minutes or less in acute care settings.\*
- Minimize the need for empirical therapy decisions during patient visits with actionable molecular results.
- ID NOW accelerates workflow and improves patient management through real-time diagnosis, reducing overcrowding and promoting cost-effectiveness.<sup>1-8</sup>
- Strengthens targeted infection control measures and helps prevent spread of disease.<sup>1-3,6</sup>



**ID NOW™** Platform performs with **accuracy equivalent to conventional RT-PCR** and delivers actionable results within the initial patient examination.\*\*

PCR = polymerase chain reaction  
POC = point of care  
RT-PCR = reverse transcription polymerase chain reaction  
VTM = viral transport medium

\*Applies to the following tests: ID NOW™ COVID-19 2.0 and ID NOW™ Influenza A & B 2.<sup>9-11</sup>  
\*\*76% of emergency department clinicians spend less than 16 minutes with a patient.<sup>12</sup>




# EXPERIENCE MORE **FLEXIBLE TESTING**

With the ID NOW™ Platform, you have the power to decide which tests to run based on patient presentation, circulating prevalence and seasonality. By reducing unnecessary testing, you can save time and money while increasing diagnostic accuracy in low-prevalence situations.

## **NOW. ONE SWAB. TWO TESTS.**

The ID NOW Platform now gives you the flexibility to test for COVID-19 only or test for COVID-19 and influenza A & B using a single patient swab sample.

SINGLE SWAB SAMPLE



● COVID-19

● Influenza A & B





# EXPERIENCE EASY INTEGRATION IN ACUTE CARE SETTINGS **NOW**

Operators can feel confident using the ID NOW™ Platform because it simplifies a normally complex procedure, providing accurate and high-quality results with limited training and no manual pipetting required.

All components are stored at room temperature, making them available on demand, right out of the box.



- The ID NOW Platform is designed for intuitive use, with operational features including on-screen guidance for every step, as well as color-coded test components and instrument parts. Diagnostic expertise is not required for operation.
- With a small footprint, the platform can be placed anywhere, allowing near-patient testing or triaging for the earliest possible results.
- Connectivity features support you in consolidating results for automated, customizable reporting that seamlessly integrates into the patient diagnostic pathway at the point of care.

**ID NOW™** enables you  
to know more **NOW**.



# LEVERAGE BETTER DIAGNOSTIC TECHNOLOGY **NOW**

ID NOW™ is the fastest rapid molecular respiratory testing solution available, using nucleic acid amplification technology (NAAT) to provide molecular results.

ID NOW is uniquely designed to be deployed in acute care settings without sacrificing quality of diagnostics through the use of nicking enzyme amplification reaction (NEAR) technology. This proven, next-generation molecular technology uses proprietary enzymes and constant temperatures to achieve the fastest available nucleic acid (DNA and RNA) amplification.

By contrast, conventional RT-PCR takes longer because it uses thermocycling, a series of temperature changes to amplify nucleic acid. ID NOW takes diagnostics further than conventional RT-PCR and other rapid molecular solutions because it doesn't require the same heating and cooling process, empowering physicians to make real-time patient care decisions.






# TAKE ACTION WITHOUT DELAY

The ID NOW™ Platform delivers accurate results in just minutes, giving you real-time access to the information you need to make actionable decisions during the first patient visit.

## ID NOW™ RESPIRATORY ASSAYS



NPA = negative percent agreement  
PPA = positive percent agreement

<sup>9</sup>Total test time when performed sequentially with a single patient swab (COVID-19 test results in 12 minutes or less and influenza A & B 2 test results in 10 minutes or less when performed in a sequential workflow). Sequential positive influenza test results after a negative COVID-19 test result will be displayed in as few as 15 minutes of total test time.

<sup>15</sup>\*\*Cycle threshold (Ct) can be used as an approximation for the initial level of virus on a sample. Low Ct numbers are associated with high levels of initial virus, and high Ct numbers are associated with low levels of virus. Lower virus concentrations (high Ct value) are usually associated with late-stage infection that is often past the time a person is infectious.





# ORDERING INFORMATION

## INSTRUMENT AND OPTIONAL ACCESSORIES

PRODUCT NAME	PRODUCT CODE
ID NOW™ INSTRUMENT	NAT-000
ID NOW™ BARCODE SCANNER	OPR2001ZWU1201
UNIVERSAL PRINTER	55115
ID NOW™ COVID-19 2.0	
24 TEST KIT	193-000
CONTROL SWAB KIT (12 POSITIVE, 12 BLANK SWABS)	192-080
COVID-19 SWAB TRANSPORT TUBE ACCESSORY PACK (24 COUNT)	190-010
ID NOW™ INFLUENZA A & B 2	
24 TEST KIT	427-000
CONTROL SWAB KIT	425-080
ID NOW™ STREP A 2	
24 TEST KIT	734-000
CONTROL SWAB KIT	734-080
ID NOW™ RSV	
24 TEST KIT	435-000
CONTROL SWAB KIT	435-080

FOR MORE INFORMATION, CONTACT YOUR LOCAL ABBOTT REPRESENTATIVE OR VISIT [GLOBALPOINTOFCARE.ABBOTT](https://globalpointofcare.abbott)

1. Nguyen Van JC, Gerlier C, Pilmis B, et al. Prospective evaluation of ID NOW™ COVID-19 assay used as point-of-care test in an Emergency Department. *medRxiv*. Published online April 4, 2021. doi:10.1101/2021.03.29.21253909.
2. Kortüm S, Krause HJ, Ott L, et al. Molecular point-of-care testing for SARS-CoV-2 using the ID NOW™ System in Emergency Department: Prospective Evaluation and Implementation in the Care Process. *medRxiv*. Published online September 13, 2021. doi:10.1101/2021.09.09.21263266.
3. Trabattoni E, Le V, Pilmis B, et al. Implementation of Alere i Influenza A & B point of care test for the diagnosis of influenza in an ED. *Am J Emerg Med*. 2018;36(6):916-921. doi:10.1016/j.ajem.2017.10.046.
4. Allen AJ, O'Leary RA, Davis S, et al. Cost implications for the NHS of using the Alere™ i Influenza A & B near patient test with nasal swabs. *Diagn Progn Res*. 2018;2:15. Published August 1, 2018. doi:10.1186/s41512-018-0031-8.
5. Peters RM, Schnee SV, Tabatabai J, Schnitzler P, Pfeil J. Evaluation of Alere i RSV for Rapid Detection of Respiratory Syncytial Virus in Children Hospitalized with Acute Respiratory Tract Infection. *J Clin Microbiol*. 2017;55(4):1032-1036. doi:10.1128/JCM.02433-16.
6. Mitamura K, Yamazaki M, Ichikawa M, et al. Clinical usefulness of a rapid molecular assay, ID NOW™ influenza A & B 2, in adults. *J Infect Chemother*. 2021;27(3):450-454. doi:10.1016/j.jiac.2020.10.009.
7. Brachmann M, Kikull K, Kill C, Betz S. Economic and operational impact of an improved pathway using rapid molecular diagnostic testing for patients with influenza-like illness in a German emergency department [published correction appears in J Clin Monit Comput. February 14, 2019;:]. *J Clin Monit Comput*. 2019;33(6):1129-1138. doi:10.1007/s10877-018-00243-2.
8. Brotons P, Nogueras MM, Valls A, et al. Impact of Rapid On-demand Molecular Diagnosis of Pediatric Seasonal Influenza on Laboratory Workflow and Testing Costs: A Retrospective Study. *Pediatr Infect Dis J*. 2019;38(6):559-563. doi:10.1097/INF.0000000000002224.
9. ID NOW™ COVID-19 2.0 Product Insert.
10. ID NOW™ Influenza A & B 2 Product Insert.
11. ID NOW™ Strep A 2 Product Insert.
12. Medscape. Physician Compensation Report 2017. Accessed June 15, 2022. <https://www.medscape.com/sites/public/physician-comp/2017>
13. ID NOW™ RSV Product Insert.
14. Abbott. Data on File. ID NOW™ Strep A 2 clinical assertion data.
15. Cevik M, Tate M, Lloyd O, Maraolo AE, Schafers J, Ho A. SARS-CoV-2, SARS-CoV, and MERS-CoV viral load dynamics, duration of viral shedding, and infectiousness: a systematic review and meta-analysis. *Lancet Microbe*. 2021;2(1):e13-e22.